AgeneBio

Pharmaceutical ManufacturingMaryland, United States2-10 Employees

AgeneBio is a small pharmaceutical company based in Baltimore, Maryland, focused on developing therapies to prevent neurodegeneration and maintain or restore cognitive function for unserved patients with amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, as well as other neurological and psychiatric disorders. Its work is grounded in decades of research, including studies from Johns Hopkins University, that point to hippocampal overactivity as a driver of cognitive impairment and neurodegeneration. AGB101 is the company’s lead candidate and is described as Phase 3-ready, aimed at addressing hippocampal overactivity. In addition, AgeneBio is pursuing a novel GABA-A alpha5 small molecule program in late discovery stage with potential applications across conditions such as aMCI, autism, and schizophrenia. Overall, AgeneBio operates within the pharmaceutical manufacturing sector, concentrating on therapies for neurological and psychiatric diseases.

Sign up for free to view info

Email Format Employee directory